IPHA
Innate Pharma S.A. Healthcare Biotechnology
6/12
Innovation Score
Patent Activity
3/3
16 patents found
FUZZY
Cash Runway
0/3
8 months of cash remaining based on current burn rate.
Cash on hand: $34.3M
Cash on hand: $34.3M
Revenue Trajectory
0/3
Revenue: $9.0M
YoY Growth: -46.7%
YoY Growth: -46.7%
Management Quality
3/3
Insider ownership: 29.8%
SBC/Revenue: 0.0%
No reverse splits detected
SBC/Revenue: 0.0%
No reverse splits detected
Key Metrics
Market Cap
$189.5M
Revenue
$9.0M
Revenue Growth (YoY)
-46.7%
Cash on Hand
$34.3M
Cash Runway
8 months
Shares Outstanding
93.8M
Insider Ownership
29.8%
SBC / Revenue
0.0%
Sector / Industry
Healthcare / Biotechnology
Patents (16)
Match type: FUZZY — company name matched partially; verify assignee
- Variable regions for NKp46 binding proteins
- Treatment of peripheral T cell lymphoma
- NKp46 binding agents
- Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
- Treatment with anti-KIR3DL2 agents
7-Step Risk Assessment
How IPHA maps to our micro cap methodology:
- Innovation Signal 16 patents identified. This suggests the company is investing in defensible IP.
- Cash Runway Check 8 months of runway. Short runway increases dilution risk — watch for capital raises.
- Revenue Trajectory -46.7% YoY growth on $9.0M revenue. Revenue declining — investigate whether this is temporary or structural.
- Management Alignment Insiders hold 29.8% of shares. SBC is 0.0% of revenue.
- Competitive Moat Review the company's 10-K for barriers to entry: patents, network effects, switching costs, regulatory approvals. This step requires manual research.
- Catalyst Identification Look for upcoming catalysts: FDA decisions, contract wins, product launches, partnerships. Check recent 8-K filings and earnings transcripts.
- Position Sizing Micro caps carry outsized risk. Consider position sizing relative to conviction level and portfolio concentration. This is a $189.5M company.
Financial Detail
Free Cash Flow
$-34.1M
FCF Yield
-18.0%
Return on Equity
N/A
Debt / Equity
N/A
Gross Margin
N/A
Profit Margin
N/A
Operating Margin
-689.6%
Price / Book
-7.39
Current Ratio
1.27
Dividend Yield
None
Share Count Change (YoY)
N/A
Share Count Change (3yr)
N/A
Free Cash Flow Trend
Insufficient Data
Consecutive Years FCF Positive
0
Disclaimer: This is an automated screening tool, not investment advice. Micro cap stocks are inherently risky with low liquidity and high volatility. The innovation score is based on publicly available data and may not reflect the full picture. Steps 5-7 of the methodology require your own research. See our full disclaimer.
Last screened: 2026-05-16